

**AN INVESTIGATION OF THE ASSOCIATION  
BETWEEN TOXIN-PRODUCING  
STAPHYLOCOCCUS, BIOCHEMICAL  
CHANGES AND JAW MUSCLE PAIN.**

A Thesis submitted to the Faculty of Dentistry, University of Sydney  
for the degree of Doctor of Philosophy.

**Neil Roland McGregor. BDS (Syd), MDS (QLD).**

December 1999

**Declaration.**

“I declare that this thesis does not contain any material which has been submitted by me previously for any degree or diploma to any University. To the best of my knowledge it does not contain any material previously published or written by another person, except where due reference is made in the text.”

**Neil McGregor:**

**Date:**

## ACKNOWLEDGEMENTS.

As a maturity onset PHD student I have found this project to be one of the most fascinating and rewarding projects in which I have ever been involved. It was not a project I had to do, but a project I wanted to do. A search for the truth! The need to question the accepted paradigms, to look at what is really known, compared with what is assumed or interpreted. The need to question and evaluate my own thoughts and perceptions. A week did not go by without some exciting new insight, the need to once again review the literature and evolve my thoughts. Initially one attempts to predict the results, however the high frequency of the “*unexpected*” soon teaches one to assess the results for what they are and not what you think they are. This approach along with the high data collection per subject allowed the repetitive reassessment of the data leading to the evolution of a better understanding of the disease entity.

I must thank Professor Iven Klineberg (my supervisor), Dr Henry Butt (Chief Microbiologist, John Hunter Hospital, Newcastle), Dr Hugh Dunstan and Professor Timothy Roberts (Department of Biological Sciences, University of Newcastle) and the laboratory / secretarial staff involved with this project and the University departments for their support and encouragement. Similarly, I would like to thank the many pain/fatigue sufferers who encouraged and inspired me to address the reasons for their suffering. I would also like to thank the critics and detractors of those with these conditions and our research effort, as they provided me with my greatest inspiration – the need to correct a significant injustice to humanity.

Finally I thank my family, past and present, for their love and support and allowing me to be in the position to make this small contribution to the betterment of humanity. To my loving wife, Pam, and children, Melanie, Alexander and Edwina, thank you for your tolerance. My parents used to say “*Never let it be said to your shame that it was a better place before you came*”. I believe that the contribution of this thesis to the understanding of pain and its potential ramifications in the treatment of sufferers allows me to fulfil this important family sentiment.

# TABLE OF CONTENTS.

Section.	Contents	Page
<b>Chapter 1.</b>	<b>Introduction</b>	
1.1	Introduction	1
1.2	Proposed hypothetical models of the aetiology of TMD.	1
1.3	Pilot study data.	5
1.3.1	First pilot study.	5
1.3.2	Second pilot study.	7
1.3.3	Third pilot study.	7
1.4	Pilot study conclusions.	8
1.5	Hypothesis	8
1.6	Aims.	8
1.7	References	9
<b>Chapter 2.</b>	<b>Onset, Pain Distribution, Symptom Prevalence and SCL-90-R Changes.</b>	
2.1	Introduction.	12
2.2	Literature review.	13
2.2.1	Prevalence of TMD/Pain in the general population.	13
2.2.2	Age and sex related findings.	14
2.2.3	Other symptoms.	15
2.2.4	Onset and associated disorders.	16
2.2.5	SCL-90-R scores and TMD.	19
2.2.6	Conclusions and aims.	19
2.3	Methods	20
2.3.1	RDC/TMD type 1a patients.	20
2.3.1.a	Patient and control selection.	20
2.3.1.b	CPRU questionnaire.	20
2.3.1.c	SCL-90-R questionnaire.	21
2.3.1.d	Pain/symptom assessment.	21
2.3.2	CFS group.	22
2.3.3	Statistical analysis.	23
2.4	Results.	23
2.4.1	RDC/TMD type 1a patients.	23
2.4.1.a	Patient characteristics.	23
2.4.1.b	Pain distribution.	24
2.4.1.c	Pain assessment.	24
2.4.1.d	Signs and symptoms.	25
2.4.1.e	Onset-related events.	27
2.4.1.f	History of infectious events.	27
2.4.1.g	Pain in long-term partners.	27
2.4.1.h	SCL-90-R group differences.	28
2.4.1.i	SCL-90-R global index associations with dimension and pain / symptom parameters.	29
2.4.1.j	Pain/symptom indicators and SCL-90-R dimension differences.	30

<b>Section</b>	<b>Contents (Continued).</b>	<b>Page</b>
2.4.1.k	SCL-90-R question response interpretation.	31
2.4.2	TMD in CFS patients.	32
2.4.2.a	CFS patients with TMD symptoms.	33
2.4.2.b	Symptoms associated with 12-month facial pain symptom frequency in CFS patients.	34
2.4.2.c	12-Month facial pain symptom severity in CFS patients.	37
2.4.2.d	12-Month TMJ pain symptom frequency in CFS patients.	37
2.4.2.e	12-Month TMJ pain symptom severity in CFS patients.	39
2.4.2.h	7-Day TMD symptoms associations in the CFS and control groups.	40
2.4.2.i	Differences in onset-related events associated with TMD in CFS patients.	42
2.4.2.j	Stress and TMD symptoms.	43
2.4.2.k	Antibiotics and TMD symptoms.	43
2.4.2.l	SCL-90-R dimension score difference between CFS and controls.	44
2.4.3	SCL-90-R dimension score associations with facial and TM Joint pain.	44
2.4.3.a	Facial pain symptom frequency.	44
2.4.3.b	Facial pain symptom severity.	45
2.4.3.c	TMJ pain symptom frequency.	46
2.4.3.d	TMJ pain symptom severity.	46
2.4.4	Post-exercise fatigue and TMD.	46
2.5	Discussion.	47
2.6	Conclusions.	53
2.7	References.	53
<b>Chapter 3. TMD and Changes in Biochemistry, Amino and Organic Acid Metabolism.</b>		
3.1	Introduction.	60
3.2	Literature review.	61
3.2.1	Overview of amino acid metabolism.	61
3.2.2	An overview of nitric oxide, amino acid metabolism and pain.	69
3.2.3	Organochlorine pesticides in polysymptomatic pain/fatigue patients.	73
3.2.4	Alteration of amino acids in polysymptomatic pain/fatigue patients.	74
3.2.5	Orofacial pain mechanisms.	76
3.2.6	Proteolysis (intracellular protein degradation).	76
3.3	Methods.	79
3.3.1	RDC\TMD type 1a patients.	79
3.3.1.a	Patient and control selection.	79
3.3.1.b	Questionnaires.	79
3.3.1.c	Confirmation of muscle pain.	79
3.3.1.d	Urine specimens and GC-MS identification.	79
3.3.2	CFS group.	81
3.3.2.a	Study population.	81
3.3.2.b	Urine specimens and GCMS compound identification.	82

<b>Section</b>	<b>Contents (Continued).</b>	<b>Page</b>
3.3.2.c	Blood sample collection and analyses.	82
3.3.2.d	Extraction of amino and organic acids from plasma.	83
3.3.2.e	Extraction of pesticide residues from plasma.	83
3.3.3	RNase-L CFS study.	84
3.3.3.a	Patient selection.	84
3.3.3.b	Blood sample collection and analyses.	84
3.3.4	Statistical analysis.	84
3.4	Results.	86
3.4.1	RDC/TMD type 1a study.	86
3.4.1.a	Patient details.	86
3.4.1.b	Urinary excretion patterns.	86
3.4.1.c	Differences in urinary metabolites in relationship to sex.	89
3.4.1.d	Differences in urinary metabolites in relationship to pain severity.	90
3.4.1.e	Differences in urinary metabolites in relationship to symptom prevalence.	93
3.4.1.f	Differences in urinary metabolites in relationship to the duration of illness.	94
3.4.1.g	Differences in urinary metabolites in relationship to sudden or gradual onset.	96
3.4.1.h	Differences in urinary metabolites in relationship to body pain distribution.	96
3.4.1.i	Differences in urinary metabolites in relationship to muscle pain/soreness.	98
3.4.1.j	Differences in urinary metabolites in relationship to fatigue.	99
3.4.1.k	Differences in urinary metabolites in relationship to SCL-90-R somatization.	100
3.4.1.l	Differences in urinary metabolites in relationship to SCL-90-R depression.	101
3.4.2	TMD pain in CFS study.	101
3.4.2.a	Patient characteristics.	101
3.4.2.b	Prevalence of TMD symptoms.	101
3.4.2.c	Gross urine parameters.	102
3.4.2.d	Urine amino and organic acids.	102
3.4.2.e	Urine amino and organic acids and gross urine data.	103
3.4.2.f	Serum amino and organic acids.	106
3.4.2.g	Serum biochemistry and red and white blood cell changes.	106
3.4.2.h	Pesticides.	109
3.4.2.i	Reported facial pain.	109
3.4.2.j	7-Day facial pain severity.	110
3.4.2.k	12-Month facial pain severity.	112
3.4.2.l	12-Month facial pain frequency.	112
3.4.2.m	7-Day TMJ pain severity.	114
3.4.2.n	12-Month TMJ pain severity.	115
3.4.2.o	12-Month TMJ pain frequency.	115
3.4.2.p	Associations between sodium, symptoms and biochemical parameters.	117

<b>Section</b>	<b>Contents (Continued).</b>	<b>Page</b>
3.4.2.q	Neutrophil count associations with symptoms and biochemical parameters.	119
3.4.2.r	Associations between basophil count symptoms and biochemical parameters.	121
3.4.2.s	Association between ALT, symptoms and biochemical parameters.	123
3.4.2.t	Association between the excitatory amino acids, symptoms and biochemical parameters.	125
3.4.2.u	Association between serum lysine, symptoms and biochemical parameters.	128
3.4.2.v	Association between urine volume, symptoms and biochemical parameters.	130
3.4.2.w	DDE and Deildrin associations with symptoms and biochemical parameters.	132
3.4.2.x	Association between antibiotic use, symptoms and biochemical parameters.	137
3.4.2.y	Association between prolonged stress, symptoms and biochemical parameters.	138
3.4.2.z	SCL-90-R somatization and depression dimensions and biochemical parameters.	138
3.4.2.aa	Sex differences in symptoms and biochemical parameters.	139
3.4.3	RNase-L Study.	145
3.4.3.a	Group differences.	145
3.4.3.b	TMD symptom associations.	146
3.5	Discussion.	148
3.6	Conclusions.	168
3.7	References.	168
<b>Chapter 4. Staphylococci and TMD.</b>		
4.1	Introduction.	181
4.2	Literature review.	182
4.2.1	Overview of staphylococcus species.	182
4.2.2	Staphylococcal toxins	183
4.2.2.a	Staphylococcal enterotoxins and toxic shock syndrome toxin.	184
4.2.2.b	Staphylococcal membrane-damaging toxins	185
4.2.2.c	Genetic regulation of staphylococcal membrane-damaging toxins.	186
4.2.2.d	Staphylococcal $\delta$ -toxin in disease pathogenesis.	188
4.2.3	Staphylococci, toxicity and chronic pain.	189
4.2.3.a	Neutrophils and nitric oxide.	189
4.2.3.b	Staphylococcus, basophils and histamine.	190
4.3	Methods.	192
4.3.1	RDC\TMD type 1a patients.	192
4.3.1.a	Patient and control selection.	192
4.3.1.b	Microbial specimen collection and processing.	192
4.3.1.c	Microbial identification.	192
4.3.1.d	Staphylococcal supernatant	193

## Table of Contents (Continued).

Section	Contents	Page
4.3.1.e	Detection of TSST-1 and SEA-SED	193
4.3.1.f	Assay for haemolytic activity	194
4.3.1.g	Definition of positive (significant) haemolysis.	194
4.3.1.h	Staphylococcal indices.	194
4.3.2	CFS microbiological, cytokine and RNase-L study.	195
4.3.3	Statistical analysis.	195
4.4	Results	196
4.4.1	RDC/TMD type 1a patients.	196
4.4.1.a	Patient and control subjects characteristics.	196
4.4.1.b	Urinary metabolites excretion patterns.	196
4.4.1.c	Staphylococcal colonisation in RDC/TMD type 1a pain patients.	196
4.4.1.d	Toxin producing staphylococcus and pain severity (VAS).	198
4.4.1.e	Toxin producing staphylococcus, illness duration, body pain distribution, symptom prevalence and age.	199
4.4.1.f	Toxin producing staphylococcus and urinary metabolite changes.	198
4.4.1.g	Toxin producing staphylococcus and sudden onset.	203
4.4.1.h	Toxin producing staphylococcus and antibiotic use at onset.	203
4.4.1.i	Toxin producing staphylococcus and SCL-90-R somatization and depression scores.	204
4.4.1.j	Toxin producing staphylococcus and symptoms.	204
4.4.2	RNase-L Study group.	205
4.4.2.a	Group differences.	205
4.4.2.b	Association between staphylococcal species and CFS.	205
4.4.2.c	Association between staphylococcal parameters and facial pain.	206
4.4.2.d	Association between staphylococcal parameters and TMJ clicking/locking.	209
4.4.2.e	Association between staphylococcal parameters, RNase-L, sIL-2r and IL-6.	209
4.4.2.f	Association between staphylococcal parameters and symptoms.	210
4.4.2.g	Association between staphylococcal parameters and stress responses.	212
4.5	Discussion.	212
4.6	Conclusion	219
4.7	References	219
<b>Chapter 5</b>	<b>5. Conclusions: Facial Muscle Pain: an Hypothesis and Future Research.</b>	
5.1	Overview.	226
5.2	Coagulase-negative staphylococcal toxaemia.	226
5.3	A model of the aetiopathogenesis of RDC/TMD type 1a muscle pain.	228
5.3.1	The mechanism of muscle pain development.	229
5.3.1.a	Spinal Hyperalgesia.	229
5.3.1.b	Kidney Diuresis.	231
5.3.1.c	Hypothalamic-Pituitary Adrenal Axis.	232
5.3.1.d	Immune cell changes.	235
5.3.1.e	Gradual onset and Duration.	236
5.3.2	Sex differences.	240



**Table of Contents (Continued).**

<b>Section</b>	<b>Contents</b>	<b>Page</b>
5.3.3	Treatment approaches.	241
5.4	Summary.	243
5.5	References.	244
<b>Appendices</b>		
1	1 <sup>st</sup> study questionnaire.	248
2	Royal North Shore Hospital study consent form.	257
3	Royal North Shore Hospital study questionnaire.	258
4	3 <sup>rd</sup> study questionnaire.	291

**List of Tables.**

<b>Table</b>	<b>Contents</b>	<b>Page</b>
<b>Chapter 1</b>		
1.1	TMD research diagnostic criteria.	1
<b>Chapter 2</b>		
2.1	Diseases and factors associated with onset of TMD disorders.	16
2.2	Forward stepwise regression analysis of pain assessment questions found important in determining the difference between the RDC/TMD type 1(a) patients and control subjects.	25
2.3	Sensitivity and specificity of questionnaire reported symptoms in RDC/TMD type 1(a) patients and control subjects.	26
2.4	Prevalence of major onset-related events in RDC/TMD type 1(a) patients.	27
2.5	Mean SCI-90-R global and dimension t-scores in RDC/TMD type 1(a) patients and control subjects.	28
2.6	The clinical characteristics of the 29 elevated muscle pain-related SCL-90-R questions.	31
2.7	The prevalence of the scalar frequency and severity responses by CFS patients and control subjects.	33
2.8	The prevalence of the combined scalar frequency and severity responses for the facial and TMJ pain per subject for the CFS patients and control subjects.	34
2.9	Summary of the Spearman rank correlation scalar responses to the 12-month frequency and severity scores of the scalar responses for facial pain for the CFS patients and the control subjects.	36
2.10a	Spearman rank correlations of the scalar responses to the 12-month TMJ pain frequency and severity scores for CFS patients and the control subjects.	38
2.10b	Spearman rank correlations of the scalar responses to the 12-month TMJ pain frequency and severity scores for CFS patients and the control subjects.	39
2.11	Spearman rank correlation analysis of the scalar responses to the 7-day face pain and TMJ pain severity scores for CFS patients and the control subjects.	41
2.12	Prevalence of onset associated events in CFS patients with TMD symptoms.	42

**List of Tables (Continued).**

<b>Table</b>	<b>Contents</b>	<b>Page</b>
2.13	Regression analysis of the differences in SCL-90-R dimension scores between the CFS and control groups and the study subjects with TMD symptoms compared with study subjects without TMD symptoms.	45
<b>Chapter 3.</b>		
3.1	T-test analysis of the Urine Excretion Data Measured in the RDC/TMD type 1a Patients and Control Subjects.	87
3.2	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with pain severity (VAS) scores in the RDC/TMD type 1a patients.	91
3.3	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with symptom prevalence in the RDC/TMD type 1a patients.	93
3.4	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with duration in the RDC/TMD type 1a patients only.	94
3.5	Summary of the t-test difference in the urinary excretion of metabolites related to a sudden or gradual onset in the RDC/TMD type 1a patients only.	96
3.6	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with the body pain regions in the RDC/TMD type 1a patients.	97
3.7	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with muscle soreness scores in the RDC/TMD type 1a patients.	98
3.8	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with fatigue scores in the RDC/TMD type 1a patients.	99
3.9	Summary of the regression and Spearman rank correlation analyses of the urinary excretion of metabolites with SCL-90-R somatization and depression scores in the RDC/TMD type 1a patients.	100
3.10	Summary of the multiple regression and t-test analysis of the changes in urine metabolites in CFS patients compared with the control group.	103
3.11	Summary of the multiple regression and correlation analyses of the association between the urinary volume, metabolite, amino acid and organic acid excretion parameters.	104
3.12	Summary of the multiple regression and correlation analyses of the association between the urinary relative abundance of amino and organic acids and the urinary excretion parameters.	105
3.13	Multiple regression and t-test analysis of the changes in serum metabolites between CFS patients and control subjects.	107
3.14	Red and White Blood Cell Parameters and Pesticide levels for CFS Patients Compared with Control Subjects using Students t-test and Standard Discriminant Function Analyses.	108

**List of Tables (Continued).**

<b>Table</b>	<b>Contents.</b>	<b>Page</b>
3.15	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the reporting of facial pain in CFS patients.	110
3.16	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the 7-day severity of facial pain in CFS patients and control subjects.	111
3.17	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the 12-month severity of facial pain in CFS patients and control subjects.	112
3.18	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the 12-month frequency of facial pain in CFS patients and control subjects.	113
3.19	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the 7-day severity of TMJ pain in CFS patients and control subjects.	114
3.20	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the 12-month severity and frequency of TMJ pain in CFS patients and control subjects.	116
3.21	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and serum sodium in the CFS patients.	117
3.22	Summary of the differences in the correlation coefficients for sodium in CFS patients with a positive 7-day facial pain response compared with those with no response.	118
3.23	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and neutrophil count in the CFS patients.	120
3.24	Summary of the differences in correlation coefficients for the neutrophil count between CFS patients with a positive 7-day facial pain response compared with those with no response.	121
3.25	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and the basophil count.	122
3.26	Summary of the univariate analyses of the association between the basophil count and the biochemical parameters in the CFS patient group and control subjects.	123
3.27	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and ALT.	124
3.28	Summary of the differences in correlation coefficients for ALT between CFS patients with a positive 7-day facial pain response compared with those with no response.	125
3.29	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and the EPM for glutamic and aspartic acids.	126

**List of Tables (Continued).**

<b>Table</b>	<b>Contents.</b>	<b>Page</b>
3.30	Summary of the differences in correlation coefficients for aspartic acid between CFS patients with a positive 7-day facial pain response compared with those with no response.	127
3.31	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and serum lysine.	128
3.32	Summary of the differences in correlation coefficients for serum lysine between CFS patients with a positive 7-day facial pain response compared with those with no response.	129
3.33	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and urine volume.	131
3.34	Summary of the differences in correlation coefficients for urine volume between CFS patients with a positive 7-day facial pain response compared with those with no response.	132
3.35	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and DDE.	133
3.36	Summary of the multiple regression and correlation analysis associations between DDE and biochemistry in CFS patients and control subjects.	134
3.37	Summary of the correlation analyses of the association between the SCL-90-R scalar symptom responses and Deildrin.	135
3.38	Summary of the multiple regression and correlation analysis associations between Deildrin and biochemistry in the CFS patients and control subjects.	136
3.39	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and 1) prolonged antibiotic use; and 2) prolonged stress; in CFS patients.	137
3.40	Summary of the multiple regression and univariate analyses of the association between the biochemical parameters and the SCL-90-R somatization and depression dimensions in CFS patients.	139
3.41	Summary of the forward stepwise regression analyses of the differences in the various TMD symptoms between females and males in the CFS patient group.	140
3.42	Analysis of the differences in Spearman rank correlation analyses for the various TMD symptoms between females and males in the CFS patient group.	143
3.43	Summary of the discriminant function and univariate analysis differences in the prevalence and concentrations of RNase-L, sIL-2r and IL-6 between the CFS patients and control subjects.	145
3.44a	Summary of the Spearman correlation analysis associations between symptoms and RNase-L in all subjects, the CFS patients and control subjects.	146
3.44b	Summary of the Spearman correlation analysis associations between symptoms and sIL-2r and IL-6 in all subjects, the CFS patients and control subjects.	147

**List of Tables (Continued).**

<b>Table</b>	<b>Contents.</b>	<b>Page</b>
3.45	Summary of the potential metabolic associations which may be effected by the various changes in urine excretion which were correlated with illness duration and pain severity.	152
<b>Chapter 4</b>		
4.1	List of staphylococcal species.	183
4.2	Staphylococcal toxins.	184
4.3	Summary of the properties of staphylococcal membrane-damaging toxins.	185
4.4	Staphylococcal characteristics for the RDC/TMD type 1a pain patients (n=29) and control subjects (n=34) and the Spearman rank correlation with pain severity (VAS) in all study subjects (n=63).	197
4.5	Spearman rank correlation analysis of the staphylococcal parameters with illness duration, body pain distribution, symptom prevalence and age.	199
4.6	Odds ratio analysis of toxin-producing CoNS (total and individual species) and body pain distribution.	199
4.7	Correlation of the urinary metabolite excretion with the number of toxin producing CoNS within the whole study group (n=63), and the RDC/TMD type 1a pain group (n=29).	202
4.8	Differences in the staphylococcus characteristics between RDC/TMD type 1a patients who reported antibiotic use at onset compared with those who did not report antibiotic use at onset.	203
4.9	Associations between toxin-producing CoNS and general body symptoms, modifying events and onset associated events.	204
4.10	Differences in the study subject characteristics, TMD parameters and staphylococcus characteristics between the CFS patients and control subjects.	205
4.11	Differences in the subject and staphylococcus characteristics between facial pain patients and subjects without face pain.	207
4.12	Spearman rank correlation analysis of the staphylococcal parameters with the 7-days severity scores for face pain and TMJ clicking/locking in all study subjects (n=63).	207
4.13	Differences in staphylococcus characteristics between TMJ clicking/locking patients and control subjects.	209
4.14	Correlation analysis between symptoms and the mean toxin-production per CoNS isolate as well as the correlation analyses weighted for the level of RNase-L.	211
<b>Chapter 5.</b>		
5.1	Symptoms associated with coagulase-negative staphylococcal toxemia.	227

## List of Figures.

Figure	Contents	Page
<b>Chapter 2.</b>		
2.1.	Plot of different measures of TMD symptom expression in relationship to the age of the study subjects.	35
<b>Chapter 3.</b>		
3.1	Overview of human amino acid metabolism.	62
3.2	Overview of glucose/alanine and alanine aminotransferase (ALT) metabolism.	63
3.3	Overview of mitochondrial and cytoplasmic urea cycle reactions for ammonia removal.	64
3.4	Summary of the metabolism of the oxidative positions of the various amino acids for provision of energy within the citric acid cycle and glycolysis.	64
3.5	Nitric oxide production, the urea cycle and argininosuccinate-aspartate shunt of the citric acid cycle.	66
3.6	Scatter plot of the tyrosine: leucine ratio and its association with symptom prevalence in all RDC/TMD type 1a study subjects.	89
3.7	Scatter plot of the tyrosine: leucine ratio and its association with pain severity in all RDC/TMD type 1a study subjects.	92
3.8	Scatter plot of the tyrosine: leucine ratio and its association with the total metabolite excreted in all RDC/TMD type 1a study subjects.	92
3.9	Scatter plot of pain severity and its association with aspartic acid excretion in all RDC/TMD type 1a study subjects.	92
3.10	Scatter plot of the urinary concentration of succinic acid in association with the duration of the illness in all RDC/TMD type 1a patients.	95
3.11	Scatter plot of the total metabolite excreted per RDC/TMD type 1a patient in relationship to the duration of TMD symptoms.	95
3.12	Scatter plot of the association between increasing number of body pain regions and the concentration of UM28 in RDC/TMD type 1a patients.	97
3.13	Aminoaciduria, metabolite depletion and pain.	151
3.14	Summary of the phases of the hyperalgesia pain response in the spinal cord related to pain severity.	154
<b>Chapter 4</b>		
4.1	Age distribution of carriage of CoNS species per subject in the RDC/TMD type 1a pain patients and control subjects.	200
4.2	Age distribution of carriage of toxin-producing CoNS species per subject in the RDC/TMD type 1a pain patients and control subjects.	201
4.3	CoPS and CoNS colony forming unit counts in the total study population in relationship to age.	201
4.4	Difference in carriage of toxin producing CoNS between patients with facial pain compared with the remaining study subjects in relationship to age.	208

**List of Figures (Continued).**

<b>Figure</b>	<b>Contents</b>	<b>Page</b>
4.5	Difference in the proportion of toxin producing CoNS between patients with facial pain compared with the remaining study subjects in relationship to age.	205
4.6	Association between RNase-L and the mean CoNS delta-toxin production per species in the facial pain patients and the remaining study subjects.	210
<b>Chapter 5</b>		
5.1	Summary of the phases of the hyperalgesia pain response in the spinal cord related to pain severity.	225
5.2	Summary of the proposed phases of the myofascial hyperalgesia pain response.	229
5.3	Hypothalamic pituitary axes and cytokine actions	233
5.4	Aminoaciduria, metabolite depletion and pain.	236
5.5	Overview of alteration in the glucose/alanine and alanine aminotransferase (ALT) metabolism with prolonged cytokine mediated changes.	238